Raymond James & Associates Cognition Therapeutics Inc Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Raymond James & Associates holds 10,000 shares of CGTX stock, worth $2,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Previous 10,000 -0.0%
Holding current value
$2,600
Previous $16,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024
BUY
$1.78 - $2.53 $17,800 - $25,299
10,000 New
10,000 $18,000

Others Institutions Holding CGTX

# of Institutions
58
Shares Held
14M
Call Options Held
0
Put Options Held
0
View Full List

About COGNITION THERAPEUTICS INC

CGTX Quotes by TradingView
  • Ticker CGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,710,700
  • Market Cap $5.9M
  • Description
  • Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...
More about CGTX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email